Three Proteins in Your Blood Predict How Fast You're Aging. Here's What You Can Do About It

RapAdmin · June 13, 2026, 7:13pm

What do you think? Will you try PectaSol-C as a longevity supplement to target galectin-3?

Yes - the data looks compelling
Not yet - will wait for more data
No - its way too early from the data I see

0 voters

RapAdmin · June 13, 2026, 10:31pm

Digging into this more… here is what the data shows regarding the trend line of Galectin-3 levels during aging, organized across the full human lifespan and corroborated by animal research:

The Galectin-3 Lifespan Trendline: What the Data Shows

The short version is that galectin-3 follows a roughly U-shaped or J-shaped curve across life — very high at birth, dropping rapidly through childhood, settling to a low adult baseline in young adulthood, then rising slowly but progressively from middle age onward. Those who accumulate it fastest track toward disease and early death; those who maintain low levels into old age are the exceptional survivors.

Phase 1: Neonatal and Early Childhood — Paradoxically High

The most surprising finding is that galectin-3 is at its highest measurable levels in infants and very young children — not in elderly people.

A 2024 French pediatric cohort study (PMID: 39151672) measured galectin-3 in 140 healthy children aged 0–18 years and established two distinct age partitions:

Children under 2 years: Upper reference limit 56 ng/mL — substantially higher than any adult reference range
Children over 2 years: Upper reference limit drops sharply to 26 ng/mL

This early peak is not pathological — it reflects galectin-3’s developmental roles in tissue morphogenesis, myelination of the nervous system, immune system maturation, and organ development. Galectin-3 at this life stage is acting as a construction manager rather than an aging driver. The rapid drop in early childhood corresponds to the completion of these developmental programs.

Studies of galectin-3 in children in relation to body fat and cardiac size (PMC5816767) confirm baseline levels in school-aged children are in the low single digits to low teens (ng/mL), far below the concerning adult elevations.

Phase 2: Young Adulthood — The Low Baseline

By early adulthood, galectin-3 stabilises at its lifetime low. The healthy blood donor reference study (PMID: 29180917) — the most systematic effort to establish age-stratified normal ranges in truly healthy adults — found:

Under 45 years: Upper reference limit 21.8 ng/mL (range: 21.0–26.1 ng/mL at 97.5th percentile)
General population median in young adults: ~10–13 ng/mL

No significant sex differences exist — men and women have comparable levels at the same age. Body weight is a meaningful modifier: adipose tissue is a source of galectin-3, so individuals with higher BMI trend toward higher baseline levels even in young adulthood.

Phase 3: Middle Age Onward — The Slow, Consistent Rise

From approximately age 30–35 onward, galectin-3 begins a gradual but measurable upward trajectory. The PREVEND population cohort (PMID: 27084804) — one of the most rigorous general-population longitudinal datasets on galectin-3 — quantified this directly:

Galectin-3 rises approximately 1.5 ng/mL between age 30 and age 75, which translates to roughly ~0.033 ng/mL per year on average, or about 3% per decade relative to baseline. That sounds modest, but it is a consistent, directional drift that compounds over decades.

The ARIC Study (PMC7670497) — measuring ~9,247 US adults at median age 62, then ~4,829 of the same people again at median age 74 — confirmed this increase longitudinally over 12 years and found that both the absolute level and the rate of increase independently predicted cardiovascular outcomes:

Higher levels at midlife (median age 62): predicted coronary heart disease, ischemic stroke, heart failure, and all-cause mortality
Higher levels at older age (median age 74): predicted heart failure and all-cause mortality (the stroke/CHD associations weaken at this age, likely due to selective survival — those with high galectin-3 who were vulnerable to CHD/stroke had already died or had disease)

The upper reference limit age-shifts to reflect this population-wide rise: over 45 years, the 97.5th percentile rises to 31.5 ng/mL — 45% higher than the equivalent threshold for younger adults.

Phase 4: Late Life and Frailty — Stratification by Health Trajectory

By the seventh and eighth decades, galectin-3 levels diverge dramatically depending on the individual’s health status — and this divergence is among the most clinically informative findings in the dataset.

The 2023 frailty study (PMC10560881) measured galectin-3 in community-dwelling older adults (mean age ~72) and found a striking stepwise gradient by frailty status:

Frailty Status	Mean Galectin-3 (ng/mL)
Non-frail	26.0 ± 5.9
Pre-frail	32.3 ± 8.1
Frail	46.3 ± 18.0

This is not a small signal. The frail population has levels nearly double those of the non-frail population of the same approximate age. The correlation held across C-reactive protein and interleukin-6 simultaneously — galectin-3 was tracking the same inflammatory/fibrotic trajectory as the canonical aging inflammation markers.

The same study confirmed this in aged mice: serum galectin-3 in frail aged mice significantly exceeded that of non-frail animals of equivalent chronological age, mirroring the human pattern.

Phase 5: Exceptional Longevity — The Centenarian Reversal

The most striking finding in the entire dataset is what happens among those who reach 100+ years without chronic disease — the so-called “centenarian dodgers.”

Bucci et al. (2015, Clinical Chemistry and Laboratory Medicine; PMID: 26479349) compared galectin-3 in two groups:

Centenarians aged 100–104, disease-free (n=81): mean galectin-3 = 2.4 ± 1.7 ng/mL
Healthy controls aged 70–80 (n=41): mean galectin-3 = 4.8 ± 2.8 ng/mL

The centenarians had half the galectin-3 of people 20–30 years younger. This is not a marginal difference — it is the clearest human evidence that sustained low galectin-3 is not merely associated with survival but appears to be a defining biological characteristic of exceptional longevity. Logistic regression confirmed that low galectin-3 (combined with low osteopontin, another fibrosis/inflammation marker) independently predicted “successful aging” status regardless of sex.

Note: these levels (~2–5 ng/mL) are far below the general adult median of 10–13 ng/mL, suggesting the centenarians represent a tail of the distribution who maintain near-neonatal-low galectin-3 into extreme old age.

Animal Data: Consistent Cross-Species Pattern

The human trendline is replicated across animal models:

Mice: A 2025 study on microglial galectin-3 in the aging mouse hippocampus (PMC11842289) found galectin-3 increases progressively with age in the brain — 6-month-old vs 12-month-old vs 24-month-old female mice show stepwise increases in hippocampal microglial galectin-3, correlated with neuroinflammation and blood-brain barrier leakage. Serum galectin-3 similarly rises with chronological age in rodents.

Frail aged mice in the 2023 study described above showed the same galectin-3/frailty correlation as humans — confirming the pathway is evolutionarily conserved and not a human-specific artifact.

This cross-species consistency is directly relevant to the Tyshkovskiy 2026 paper’s finding of LGALS3 as a universal transcriptomic hallmark of aging across mice, rats, macaques, and humans — the protein-level trendline data in humans and rodents aligns with the gene-expression-level data in the transcriptomic analysis.

Important Confounders That Affect Interpretation

Three variables significantly modify galectin-3 levels independently of aging per se:

Kidney function: Galectin-3 is cleared renally. Any degree of chronic kidney disease (CKD) elevates plasma galectin-3 independently of the inflammatory/fibrotic state. Since kidney function declines with age in most people, some of the observed age-related rise in galectin-3 reflects worsening renal clearance rather than purely increased production. This is why the reference interval literature emphasises adjusting for eGFR when interpreting individual measurements.

Blood group: Galectin-3 binds certain blood group antigens on red blood cells, affecting how much circulates freely in plasma. Blood type is a meaningful but often-unaccounted-for confounder in population studies.

Body weight/adiposity: Adipose tissue produces galectin-3. Higher BMI elevates baseline levels, which is part of why obesity is associated with worse cardiovascular outcomes — galectin-3 is one of the mediating mechanisms.

Summary: The Lifespan Trendline in Numbers

Life Stage	Approximate Galectin-3 (median, ng/mL)	Notes
Neonates / infants (<2 yrs)	Up to 56 (URL)	Developmental high; not pathological
Children (2–18 yrs)	~5–15	Rapid drop from infant peak
Young adults (20s–30s)	~10–13	Lifetime low baseline
Middle age (40s–50s)	~11–15	Slow upward drift begins
Older adults (60s–70s)	~13–17 (median); up to 31 (97.5th %ile)	Acceleration with comorbidities
Frail elderly (70s+)	~32–46+	Strong frailty correlation
Centenarian dodgers (100+)	~2.4	Exceptional longevity = lowest levels

The trendline is clear: galectin-3 is a biological marker that rises with inflammaging, organ fibrosis, metabolic dysfunction, and frailty accumulation — and the people who defy the normal aging trajectory maintain levels that are, paradoxically, closer to those of young adults than to age-matched peers. This is arguably the strongest argument for galectin-3 inhibition as a longevity strategy: it is not merely correlated with disease outcomes but appears to define the biological difference between normal aging and exceptional aging.

RapAdmin · June 13, 2026, 10:39pm

What scientific and clinical evidence is there that galectin-3 is causal in age-related pathologies, and not just associative?

The causality question is the right one to ask — and the answer is nuanced: the evidence is substantially stronger than pure association, but not uniformly so across pathologies. Here is the full picture, organized by the quality of causal inference each study design provides.

Evaluating Causality: The Evidence Hierarchy

Five classes of evidence bear on this question, ranked from strongest to weakest causal inference:

Gain-of-function injection experiments (most direct)
Loss-of-function genetic knockout models
Convergent pharmacological inhibition (confirming the knockout phenotype via a different mechanism)
Mendelian randomization (genetic causality in humans)
Mechanistic pathway experiments (not causal by themselves, but establish the molecular machinery)

1. Gain-of-Function Experiments — The Strongest Evidence

The most direct causal test is: take a healthy animal, add galectin-3, and observe whether pathology develops. This has been done.

Cardiac fibrosis: De Boer et al. (AHA Circulation: Heart Failure, 2012) infused recombinant galectin-3 directly into the pericardial sac of normal, healthy rats — animals with no prior disease — and documented the development of cardiac fibrosis, increased collagen I/III ratio, and measurable ventricular dysfunction. This is not association: you take a healthy heart, add the protein, and it becomes fibrotic. Separately, isolated cardiac fibroblasts exposed to recombinant galectin-3 showed dose-dependent proliferation, differentiation into myofibroblasts, and increased collagen production. The fibrogenic mechanism is direct.

This is the closest you can get to causality short of a human RCT. Galectin-3 is sufficient to produce cardiac fibrosis in the absence of any other pathological trigger.

2. Genetic Knockout Evidence — Loss of Function

Lgals3-/- mice (galectin-3 gene deleted) have been studied across multiple age-related pathology models:

Heart failure: In wild-type mice subjected to angiotensin II infusion or transverse aortic constriction (pressure overload models of HF), knockout animals developed expected left ventricular hypertrophy but were protected from left ventricular dysfunction and fibrosis — the histological and functional differences between WT and KO were large and reproducible. In a separate genetic model of cardiomyopathy (desmin-deficient mice), genetic ablation of galectin-3 led to preservation of cardiac function over a 12-month monitoring period. (Springer CMLS, 2022)

Bone loss: PMID 30886760 (Bone Research, Nature) — Lgals3-deficient mice showed enhanced cortical bone expansion with aging and significant protection from age-related trabecular bone loss, particularly in females. The mechanism was increased osteoblastogenesis without compensatory osteoclast activation. Galectin-3 normally suppresses bone formation; removing it allows bone mass to be maintained into old age.

Atherosclerosis: In ApoE-/- mice (a standard atherosclerosis model), galectin-3 mRNA and protein were elevated 12–16× over wild-type controls. Galectin-3 inhibition or gene suppression in this model attenuates plaque development. Galectin-3 appears to drive foam cell formation, vascular smooth muscle cell migration, and calcification through the AMPK/TXNIP pathway.

3. Convergent Pharmacological Inhibition

When knockout mice and pharmacologically inhibited mice show the same phenotype, this eliminates the concern that the knockout result was a developmental artifact or compensatory effect from lifelong gene deletion.

In the cardiac fibrosis models, treatment with modified citrus pectin (a galectin-3 competitive inhibitor) in wild-type mice replicated the protection seen in Lgals3-/- mice: reduced fibrosis, preserved LV function, attenuated adverse remodeling. This convergence — genetic and pharmacological inhibition producing the same phenotype — substantially strengthens the causal inference.

4. Mendelian Randomization — Genetic Causality in Humans

MR uses common genetic variants (SNPs) that instrumentally raise or lower plasma galectin-3 levels to estimate causal effects in humans, bypassing confounding. The results are positive but inconsistent:

Positive evidence: Trinder et al., Circulation (2021) — a large proteomics-based MR study across >50,000 individuals identified galectin-3 as one of only 8 proteins (out of 44 that were observationally associated with heart failure) with evidence of causal association with heart failure risk. This is the highest-powered study on this question and provides the strongest human genetic evidence for causality.

Conflicting evidence: A smaller MR study specifically examining ST2 and galectin-3 PMC9037587 found no causal association between genetically predicted galectin-3 and heart failure using inverse variance weighted analysis.

Peripheral artery disease: A 2024 MR study (PMC10794734) found positive associations between galectin-3 and PAD severity.

Parkinson’s disease: A 2024 two-sample MR (PMC11499214) found associations between galectin-3 and Parkinson’s disease risk.

The inconsistency across MR studies is common in the protein biomarker literature and typically reflects differences in genetic instruments (the specific SNPs used as proxies), population stratification, and outcome definitions. The large Trinder Circulation study is substantially better powered and methodologically more rigorous than the conflicting smaller study. The weight of MR evidence modestly supports causality in HF, but does not clinch it.

5. Mechanistic Pathway Evidence

These experiments establish how galectin-3 produces pathology rather than whether it does, but the specificity of the mechanisms is itself informative:

Direct TGF-β receptor binding: A 2025 study (ScienceDirect, PMC, Environmental Pollution) showed that senescent endothelial cells secrete galectin-3 as a SASP component, and that secreted galectin-3 directly binds TGFBR1 (TGF-β receptor 1) on the surface of lung fibroblasts, triggering fibroblast-to-myofibroblast transition. This is a direct molecular mechanism, not a correlative observation — galectin-3 is acting as a ligand for a pro-fibrotic receptor.

Senescent cells as the source: Senescent mesenchymal stem cells express and secrete high levels of galectin-3 as part of SASP. This places galectin-3 causally downstream of cellular senescence and upstream of fibrosis — exactly the chain predicted by the Tyshkovskiy data. The pathway is: senescence → galectin-3 secretion → TGFBR1 activation → fibrosis. Each step is mechanistically documented.

Vascular calcification: Galectin-3 induces vascular smooth muscle cell calcification through the AMPK/TXNIP pathway (PMC9271303) — a direct mechanism contributing to arterial stiffening and atherosclerosis independent of lipid deposition.

Cancer immune evasion: Galectin-3 promotes polarization of macrophages toward the M2 (pro-tumor, immunosuppressive) phenotype, suppresses T and NK cell cytotoxicity, and induces angiogenesis. These are discrete, testable mechanisms. A 2023 Nature Reviews Drug Discovery review frames galectin-3 as a “regulatory circuit” driver in both cancer and fibrosis — a systems-level view of its causal role.

6. Clinical Intervention Evidence — The Hardest Test

Clinical trials testing galectin-3 inhibitors provide the ultimate translational test of causality:

Belapectin (GR-MD-02) in NASH cirrhosis — the NAVIGATE trial, presented at AASLD 2025, showed that belapectin 2 mg/kg produced a lower incidence of new varices, reduced liver stiffness progression by FibroScan, and reduced YKL-40 (a galectin-3–associated fibrosis biomarker) in a higher proportion of patients than placebo. This is a positive signal from a Phase 2/3 human trial. It is not yet a Phase 3 primary endpoint win, but it aligns with the mechanistic prediction.

GB0139 (Galecto) in IPF — the 52-week Phase 2b GALACTIC-1 trial failed its primary endpoint (FVC decline rate). This is a genuine setback and should not be minimized. However, interpretive caution applies: the trial used inhalational delivery targeting the lung, which may not achieve systemic galectin-3 inhibition; IPF is a particularly refractory endpoint; and the patient population had advanced disease. A failed drug trial in a difficult indication does not refute the causal biology — it means that specific drug, route, dose, and patient selection did not produce the result in that trial.

Honest Summary of the Causal Picture

Evidence Type	Strength	Verdict
Gain-of-function injection (healthy rat → fibrosis)	Strongest	Galectin-3 is sufficient to cause cardiac fibrosis
Lgals3-/- knockout protection (heart, bone, vessel)	Strong	Galectin-3 is necessary for fibrotic pathology in multiple organs
Convergent pharmacological inhibition	Strong	Confirms knockout phenotype is mechanism-specific, not developmental artifact
Mechanistic pathway (TGFBR1 binding, SASP, AMPK/TXNIP)	Moderate	Specific molecular machinery identified
Mendelian randomization (humans)	Moderate, inconsistent	Causal signal in HF from best-powered study; weaker in smaller studies
Clinical trials (belapectin positive; GB0139 failed)	Mixed	Translation to human disease not yet definitively established

The bottom line: Galectin-3 is causally implicated in cardiac fibrosis and heart failure by the most direct experimental evidence available in animal models — gain-of-function injection and genetic/pharmacological loss-of-function with convergent phenotypes. The human genetic (MR) evidence is supportive but not conclusive. The clinical trial data is directionally positive for liver fibrosis (belapectin) and negative for pulmonary fibrosis (GB0139), though trial design confounds interpretation of the latter. The mechanistic pathway from senescence → galectin-3 secretion → TGFBR1 activation → fibrosis is now documented at each step.

This is substantially above the level of pure association, but the human translational evidence is incomplete — which is the honest state of the science as of mid-2026.

Sources:

RapAdmin · June 13, 2026, 10:43pm

What options are available for people who want to get their Galectin-3 levels tested?

Testing galectin-3 is significantly more accessible than most biomarkers in the longevity space — it’s FDA-cleared and available through multiple channels, including without a physician’s prescription. Here’s the full landscape:

Option 1: Direct-to-Consumer Lab Testing (No Physician Required)

The most accessible route for self-directed testing. You order online, visit a local draw site (typically a LabCorp or Quest patient service center), and receive results digitally in 3–6 business days. No doctor’s appointment needed.

Available services (all using LabCorp test code 004110 or Quest 92768):

Service	Price (approx. June 2026)	Notes
Ulta Lab Tests	~$92	Lowest price found
Walk-In Lab	~$149	Widely available draw sites
Request A Test	~$159	Broad coverage, easy ordering
Life Extension Lab Testing	~$95–120	Same LabCorp infrastructure

These services proxy through LabCorp or Quest’s lab network, so analytical quality is identical regardless of which portal you order through. The price differences reflect only the intermediary margin.

Note on state availability: Direct-to-consumer lab testing is not available in New York, New Jersey, and Rhode Island without a physician order — those states require physician authorization for all lab tests.

Option 2: Through a Physician (Insurance-Eligible)

Galectin-3 is FDA 510(k)-cleared as a heart failure biomarker, which means it has an ICD-10 billing code and can be covered by insurance when ordered for a cardiac indication. If you have any history of hypertension, heart failure, dyspnea, edema, or elevated BNP/NT-proBNP, a physician can order it with a plausible cardiac justification and insurance will likely cover it.

LabCorp test options:

Galectin-3 alone (004110)
Galectin-3 + NT-proBNP panel (142005) — the combination most used clinically in HF assessment
Galectin-3 + BNP panel (140080)

Mayo Clinic Laboratories (GAL3, test code 86202) runs its own galectin-3 ELISA (not a send-out to LabCorp) using an FDA 510(k)-cleared assay. This is physician-order only, and the result is processed at Mayo’s reference lab. This is the best route if you’re working with an academic medical center or if you want a Mayo-validated result in your medical record.

Functional medicine and longevity medicine physicians (Peter Attia-style practices, membership-model clinics) are increasingly familiar with galectin-3 as a longevity marker and will often order it without requiring a cardiac diagnosis as justification.

Option 3: Olink Proteomics (The Tyshkovskiy 2026 Panel)

The UK Biobank data that places galectin-3 as a top mortality predictor used Olink Explore panels — the same platform that can simultaneously measure GPNMB, CDKN1A/p21, and hundreds of other proteins from a single blood draw. This is the most scientifically complete option but also the most specialized.

Olink proteomics is available as a clinical research service through:

Academic medical centers (UCSF, Mayo, Mass General, etc.) that have Olink instruments or partnerships with Discovery Life Sciences
Specialty labs like Discovery Life Sciences (a commercial CRO with Olink capability)
Some longevity medicine clinics that offer broad proteomics panels

This is not a standard clinical order — it’s typically run as part of a research protocol or via a specialty longevity clinic arrangement. Cost is substantially higher ($500–2,000+ depending on panel size and clinical framing). If you want the same Olink proteomics measurement used in the Tyshkovskiy study specifically, this is the only path — standard ELISA-based galectin-3 (LabCorp/Quest) does not measure the other two Tyshkovskiy biomarkers (GPNMB, p21).

How to Interpret Your Result

The reference range differs between the two major clinical assays (LabCorp uses the BG Medicine assay; Mayo uses an independent ELISA), so compare your result to the ranges from the assay you used.

General interpretation framework based on published data:

Range (ng/mL)	Interpretation
<10	Below population median for adults; characteristic of exceptional aging (centenarian “dodger” range: ~2–5)
10–17.6	Normal adult range; below 90th percentile in healthy donors
17.6–22.1	90th–97.5th percentile; borderline elevated; associated with increased mortality risk
>22.1	Above 97.5th percentile upper reference limit; associated with significantly elevated all-cause mortality and cardiac risk in multiple large cohorts
>25	Warrants cardiac workup (HF, CKD, hepatic fibrosis screening)

Three critical confounders to factor in before interpreting your number:

Kidney function: Galectin-3 is renally cleared. Impaired eGFR elevates plasma galectin-3 independently of its production. Always check eGFR alongside galectin-3 — if your creatinine is elevated, your galectin-3 result needs to be interpreted against CKD-adjusted norms.
Age: The population median rises ~0.033 ng/mL/year. A result of 18 ng/mL means something different at age 40 versus age 72.
Blood type: Galectin-3 binds certain blood group antigens, which affects free plasma levels. Less well-characterized than the kidney confounder, but worth noting.

Practical Recommendation

For most self-directed longevity testers, the optimal path is:

Start with Ulta Lab Tests ($92) using LabCorp 004110 — no physician needed, fastest and cheapest
Pair it with a basic metabolic panel (available same session) to get eGFR simultaneously so you can correctly interpret the galectin-3 result
Retest every 6–12 months if implementing a galectin-3 inhibition protocol (PectaSol-C), since the biomarker’s value is in tracking change over time, not just a single point-in-time measurement
Upgrade to Olink proteomics via a longevity medicine clinic if you want the full Tyshkovskiy panel (GPNMB + p21 + galectin-3) — though this costs significantly more and requires physician partnership

Sources:

RapAdmin · June 13, 2026, 11:03pm

What is the dose / response of PectaSol-C on Galectin-3 levels? Are there other factors or variables the might impact the dose/response relationship, such as age, or absolute level of Galectic-3 levels (e.g. are higher Galectin-3 levels more responsive or less responsivle to PectaSol-C dosing?

This is one of the most important — and most misunderstood — questions in the PectaSol-C literature. The honest answer is that the data are sparse, the one well-powered human RCT produced a null result, and there is a fundamental conceptual issue with how dose-response is typically framed for this compound. Let me break this down precisely.

The Core Conceptual Problem: Mechanism vs. Biomarker

Before addressing dose-response data, there is a critical distinction that most consumer-facing information blurs:

PectaSol-C is a competitive inhibitor of galectin-3’s carbohydrate recognition domain (CRD). It competes with galectin-3’s natural binding targets — it does not reduce galectin-3 production, accelerate galectin-3 clearance, or degrade the protein. Competitive inhibition by mass action blocks what galectin-3 does, not how much of it circulates.

This means serum galectin-3 concentration and galectin-3 activity are pharmacodynamically separable. A drug that fully blocks galectin-3’s binding to TGFBR1 or cell-surface glycoproteins could, in principle, produce zero measurable change in serum galectin-3 ng/mL while still abolishing its fibrogenic signaling. Measuring serum Gal-3 as a readout of MCP efficacy may therefore be a category error — you would need a downstream marker of galectin-3 signaling (collagen synthesis rates, TGF-β pathway activation, SASP component levels) to properly assess pharmacodynamic engagement.

This is not an excuse for a null result — it is genuine mechanistic ambiguity that the clinical trials have not resolved.

The Only Rigorous Human RCT: JACC 2021 (Vergaro/Lau et al., n=68)

The most methodologically complete human study is Lau et al., JACC: Basic to Translational Science (2021), published out of a UT Southwestern collaboration. This was a double-blind randomized placebo-controlled trial in hypertensive adults.

Design: 68 participants with galectin-3 at or above the 50th sex-specific percentile (threshold: ≥13.1 ng/mL in men, ≥14.3 ng/mL in women) were randomized to PectaSol-C 4.8 g × 3/day (14.4 g/day total) or matching placebo for 6 months.

Galectin-3 levels — exact data from Table 2:

Group	Baseline (ng/mL)	6 months (ng/mL)	Change
Placebo	17.6 ± 4.1	17.1 ± 10.3	−0.48
PectaSol-C (14.4 g/day)	17.9 ± 3.5	17.9 ± 6.8	+0.01
Between-group p			p = 0.81

Result: MCP produced no measurable change in circulating galectin-3. The between-group difference was p = 0.81 — statistically indistinguishable from placebo, and the direction in the treatment arm was a fractional increase rather than decrease.

Primary endpoint (collagen metabolism markers): Not met. PICP, PIIINP, CITP, and MMP-1 were unchanged. There was a borderline elevation in PIIINP in the MCP arm (p = 0.054, not meeting the Bonferroni-corrected threshold of p = 0.0125), which was in the unexpected direction — collagen synthesis appeared to increase slightly rather than decrease.

Secondary endpoints (vascular stiffness, diastolic function, eGFR): No significant between-group differences. Modest within-group signals in LV mass index and mitral deceleration time in the MCP arm, but these did not survive between-group comparison.

Critically important caveats the authors themselves raise:

First, adherence was only 65% in the MCP arm versus 88% in placebo — primarily due to GI side effects (bloating, nausea). This means the effective dose delivered was substantially less than 14.4 g/day in many participants.

Second, the trial was significantly underpowered: 68 randomized, only 52 completing the study. It was designed as a proof-of-concept trial, not a definitive efficacy study.

Third — and most directly relevant to your question — the authors explicitly hypothesized that the null result might reflect insufficient baseline galectin-3 elevation. The exact quote: “It is conceivable that treatment with MCP may have demonstrated greater clinical benefit in individuals with higher baseline Gal-3 levels or more advanced fibrosis.” They enrolled at the ≥50th percentile (mean ~17–18 ng/mL), which is a relatively modest elevation. No subgroup analysis by baseline Gal-3 level was performed.

The Prostate Cancer Phase II Study (Keizman/Eliaz et al., Nutrients 2021, n=59)

The Nutrients 2021 Phase II trial at 14.4 g/day for 6 months measured galectin-3 at all time points, but — remarkably — presented no galectin-3 data in the results section. The methods confirm Gal-3 was drawn, but the results, tables, and discussion contain only PSA trajectory data. The Gal-3 data were either not analyzed for this publication or reserved for a separate report that has not appeared in the literature as of mid-2026. This is a significant gap.

Preclinical Dose-Response Data (Animal Studies)

Animal studies show that MCP reduces galectin-3 expression in disease tissues, which is distinct from serum level changes:

Mouse acute kidney injury (1% MCP in drinking water): Reduced galectin-3 expression in kidney tissue, reduced fibrosis, macrophage infiltration, and inflammatory cytokines. PMC3072992
Rat gastric ulcer model: Approximately 3-fold reduction in tissue galectin-3 concentration.
Rat heart failure model: Reduced myocardial galectin-3 expression alongside reduced collagen deposition and improved cardiac function.

These results measure tissue galectin-3 expression (via immunohistochemistry or tissue ELISA), not circulating serum galectin-3. The distinction matters: MCP may suppress local Gal-3 production in inflamed or fibrotic tissue by reducing the inflammatory feedback loop — a different mechanism from blocking circulating Gal-3.

Variables That Would Theoretically Affect Dose-Response

The data to directly answer most of these are absent from published human trials, but the mechanistic framework suggests the following:

Baseline galectin-3 level: The most biologically plausible modifier. Competitive inhibitors work by mass action — at higher ligand concentrations (more galectin-3), you need more inhibitor to achieve the same percent occupancy of Gal-3’s CRD. If MCP achieves a fixed total inhibitory capacity at 14.4 g/day, then someone with Gal-3 at 40 ng/mL would have a smaller fraction of their Gal-3 blocked than someone at 15 ng/mL. Counterintuitively, this means people with higher baseline levels may need higher doses (not that they are more responsive). The JACC trial hypothesis points in the same direction from the other angle: that people with higher elevation might see a larger absolute benefit even if the percentinhibition is similar or lower.

Renal function: The single strongest cross-sectional predictor of Gal-3 levels in the JACC trial was eGFR (p = 6 × 10⁻⁷). In people with reduced kidney function, a large fraction of circulating galectin-3 elevation reflects impaired clearance, not increased production or fibrotic signaling. MCP competitive inhibition does nothing to address clearance-driven elevation. This means that in people with CKD, serum Gal-3 may remain elevated despite effective inhibition of galectin-3’s biological activity — and their apparent “non-response” by Gal-3 blood level would be misleading.

Age: Not tested as a response modifier in any published trial. Age affects both baseline Gal-3 levels (higher with age) and renal function (lower eGFR with age), creating a compound confounder. Whether older individuals have greater or lesser MCP-mediated reduction in Gal-3 activity is genuinely unknown.

Sex: Women have modestly higher baseline Gal-3 than men (13.0 ± 4.7 vs 12.2 ± 3.6 ng/mL in the JACC screening sample). Whether sex modifies MCP response has not been tested.

Disease state and source of Gal-3 elevation: In active fibrotic disease (liver cirrhosis, IPF, advanced HF), galectin-3 is being actively produced by myofibroblasts and M2 macrophages. In that setting, MCP has more active Gal-3 signaling to interrupt, and the feedback loop suppression may reduce tissue production. In healthy aging with modest Gal-3 elevation from senescent cells, the dynamics may be different and the signal smaller.

Adherence and GI tolerance: The JACC trial’s 65% adherence rate in the MCP arm is a real-world constraint. At 14.4 g/day, a significant minority of people experience enough GI discomfort to reduce dosing. The effective dose-exposure in that trial was probably closer to 9–10 g/day on average.

In Vitro Binding Affinity: A Context-Setter

In cell-based assays, MCP inhibits galectin-3-mediated cell adhesion with an IC50 in the range of 0.1–1 mg/mL. This is a relatively weak affinity compared to small-molecule galectin-3 inhibitors like GB0139 (a thiodigalactoside with IC50 in the nM range). MCP works through multivalent galactose interactions with the CRD rather than high-affinity single-site binding. The high oral doses required (14.4 g/day) reflect this modest binding affinity — you need a large mass of competitive inhibitor to achieve meaningful CRD occupancy at physiological concentrations.

Honest Bottom Line

The dose-response picture for PectaSol-C on circulating galectin-3 levels, as of mid-2026, is:

What is established: 14.4 g/day for 6 months does not measurably reduce circulating serum galectin-3 protein concentration in humans with modestly elevated levels (≥50th percentile, mean ~17–18 ng/mL). This is from the only RCT with Gal-3 as a measured outcome.

What is not established: Whether higher doses, longer duration, higher baseline Gal-3, or more severe fibrotic disease states would produce different results. The JACC authors’ hypothesis that more elevated baseline Gal-3 might be required to see effect is plausible but untested.

The deeper uncertainty: Whether serum Gal-3 concentration is the right pharmacodynamic readout at all. MCP’s mechanism (competitive CRD blockade) does not predict serum level reduction. The clinical rationale for PectaSol-C rests more on PSA trajectory data in prostate cancer and preclinical fibrosis data than on demonstrated serum galectin-3 reduction in humans.

The actionable implication for self-monitoring: If you are using serum galectin-3 testing to track PectaSol-C efficacy, a stable or modestly unchanged serum galectin-3 does not necessarily mean the drug is failing. Conversely, the JACC trial gives no support to the claim that this dose reliably reduces circulating Gal-3. The honest monitoring strategy would focus on downstream functional markers — blood pressure trajectory, echocardiographic diastolic function, inflammatory markers (CRP, IL-6), and PSA kinetics if applicable — rather than Gal-3 concentration alone.

Sources:

RapAdmin · June 13, 2026, 11:07pm

Are there any other chemicals or compounds that are commercially available that are inhibitors of galectin-3?

The galectin-3 inhibitor landscape spans four distinct tiers — consumer supplements, investigational drugs in active trials, discontinued clinical candidates, and natural compounds with indirect or partial activity. Here is the full picture, organized by commercial accessibility and evidence quality.

Tier 1: Consumer Supplements with Direct Galectin-3 Inhibitory Mechanism

1. Modified Citrus Pectin (PectaSol-C and alternatives)

Already covered in detail. The benchmark. Competitive CRD inhibitor via galactose oligosaccharides; <10 kDa MW required for systemic absorption; human trial data (PSA kinetics in prostate cancer); did not reduce serum Gal-3 in the JACC hypertension RCT. Commercially available, widely sourced.

2. Fucoidan

The most scientifically interesting commercially available alternative, and the least-discussed in longevity circles. Fucoidan is a sulfated polysaccharide derived from brown marine algae (Fucus vesiculosus, Undaria pinnatifida, and related species). It has a long food-safety record and is sold widely as a supplement.

Mechanism: Fucoidan inhibits galectin-3 through a different structural basis than MCP — its sulfate groups interact with galectin-3’s CRD, and it also appears to suppress galectin-3 secretion from macrophages and fibroblasts, which is upstream of the competitive inhibition that MCP provides. This is potentially a more complete inhibition: reducing both Gal-3 production and its downstream signaling.

Most recent data: A 2024 mouse study (Biomedicines, PMC11673818) subjected mice to pressure-overload cardiac surgery (a standard HF/fibrosis model) and treated with fucoidan at 1.5 or 7.5 mg/kg/day. Fucoidan prevented galectin-3 upregulation, reduced collagen deposition, reduced inflammatory cell infiltration, and attenuated cardiac remodeling — with dose-dependent effects. Importantly, the mechanism appeared to involve reducing Gal-3 secretion (not just competitive binding), which would predict actual reduction in circulating Gal-3 levels — a key distinction from MCP’s mechanism.

Human dose extrapolation (HED): Mouse study used 1.5–7.5 mg/kg/day. Using the standard allometric scaling formula (mouse Km = 3, human Km = 37): HED = Animal dose × (3/37) = approximately 0.12–0.6 mg/kg/day, or roughly 10–42 mg/day for a 70 kg adult. This is far lower than typical fucoidan supplement doses, which usually run 500 mg–3 g/day — suggesting commercial doses likely exceed the pharmacologically active threshold by a wide margin.

Limitations: The evidence base is entirely preclinical. No human RCTs on fucoidan and galectin-3 exist. MW and sulfation degree vary substantially between commercial fucoidan products (different algae species, extraction methods), and these parameters affect biological activity. There is no standardized fucoidan specification analogous to PectaSol-C’s <10 kDa / DE ≤5% profile.

Availability and cost: Fucoidan supplements are sold by many brands (Swanson, Now Foods, Nutricology, Modifilan, Life Extension). Prices range from ~$0.20–1.50/day at typical doses. Several brands specify the algae source; Undaria(wakame) and Fucus vesiculosus (bladderwrack) are most studied.

Tier 2: Investigational Pharmaceutical Compounds (Not Commercially Available)

These are important to understand because they represent where the pharmacology is going, and some may eventually be accessible through clinical trials.

3. Selvigaltin (GB1211) — Galecto Biotech

The most potent orally bioavailable galectin-3 inhibitor in clinical development. A synthetic small molecule (thiodigalactoside derivative) with extremely high affinity for the Gal-3 CRD.

Affinity: KD = 25 nM for human galectin-3, KD = 12 nM for rabbit galectin-3. This is roughly 4–5 orders of magnitude more potent than MCP (which inhibits at IC50 ~ 0.1–1 mg/mL, equivalent to ~10,000–100,000 nM range).

Clinical development: Phase 1 first-in-human data published 2023 (PMC10010643) — good safety and pharmacokinetics. The GALBA-1 bioavailability study (2024) established tablet vs. capsule formulation parameters. A hepatic impairment pharmacokinetics study was published in 2024. The drug is being developed for liver fibrosis/cirrhosis and MASH. Phase 2 efficacy data are not yet published as of mid-2026.

Status: Investigational only. Not available commercially. Not acquirable as a supplement. Clinical trial enrollment is the only access path.

4. Belapectin (GR-MD-02) — Galectin Therapeutics

A galactomannan polysaccharide (structurally different from MCP — mannose-galactose polymer rather than galactose-rhamnogalacturonan). Given intravenously, not orally.

Status: Phase 3 planning stage for NASH cirrhosis after NAVIGATE trial positive signals. Not commercially available — not accessible to consumers. Research-use chemical suppliers (MedChemExpress, AbMole) sell it, but explicitly for laboratory use only, not human consumption.

5. GB0139 (TD139) — Galecto Biotech (Inhaled)

A thiodigalactoside galectin-3 inhibitor delivered by inhalation. Phase 2b GALACTIC-1 trial in IPF failed its primary endpoint in 2023; development discontinued. Not commercially available and no longer in active development for IPF. A different formulation for other indications may continue — unclear.

Tier 3: Natural Compounds with Indirect or Partial Galectin-3 Activity

These are widely commercially available but their galectin-3 effects are either indirect (modulating downstream signaling rather than blocking the CRD directly), weak, or based primarily on in vitro data without confirmed systemic target engagement.

6. Quercetin

Quercetin has the strongest indirect evidence among polyphenols. A 2024 study found quercetin attenuates atherosclerotic inflammation by inhibiting the galectin-3/NLRP3 signaling pathway — specifically blocking galectin-3’s activation of the NLRP3 inflammasome, a key step in sterile inflammation and SASP amplification. This is not direct CRD competitive inhibition; rather, quercetin interferes downstream at the galectin-3 → NLRP3 → NF-κB cascade. Whether this represents meaningful galectin-3 pathway inhibition in vivo at supplemental doses is uncertain.

Quercetin is widely available (500 mg–1 g/day typical doses) and is already in the Tyshkovskiy-based longevity stack for its senolytic properties (in the D+Q dasatinib + quercetin combination discussed in prior sessions). The galectin-3 pathway modulation is a secondary mechanism on top of its primary p21 pathway effects.

Bioavailability caveat: Quercetin alone has poor oral bioavailability (~1–7%). Phytosome formulations (Sophora japonica–derived quercetin phytosome, e.g., Quercefit) or EGCG co-administration substantially increase absorption.

7. Luteolin

A flavonoid found in celery, parsley, thyme, and chamomile. Listed as a galectin-3 inhibitor in several pharmacological reviews and in the Santa Cruz Biotechnology galectin-3 inhibitor catalogue. The mechanism appears to be similar to quercetin — indirect modulation of Gal-3 signaling pathways rather than direct CRD competitive binding. In vitro data support galectin-3 pathway inhibition in cancer cell models. Limited in vivo data. Commercially available as a supplement (50–500 mg/day typical doses).

8. Curcumin / Turmeric

Curcumin has pleiotropic anti-inflammatory effects that overlap with galectin-3 downstream pathways (NF-κB, TGF-β, macrophage polarization). Cited alongside MCP in some formulation literature for potential synergy. No direct CRD binding data. Primary mechanism of galectin-3-relevant effects is through TGF-β pathway suppression and macrophage M1/M2 polarization balance. Commercially ubiquitous; bioavailability is highly formulation-dependent (standard curcumin ~1–3% absorbed; phospholipid complex formulations e.g., Meriva, Longvida substantially better).

9. EGCG (Epigallocatechin Gallate)

Green tea catechin with lectin-binding properties. EGCG contains galloylated catechin structures with some affinity for sugar-binding proteins including galectins. Evidence is primarily in vitro and in cancer cell models. No direct galectin-3 CRD binding affinity data published. Commercially available in concentrated form (green tea extract standardized to ≥45% EGCG).

Comparative Summary Table

Compound	Type	Mechanism	Potency vs. Gal-3	Human Evidence	Commercial Availability	Approx. Cost/Day
PectaSol-C	Polysaccharide	Direct CRD competitive inhibitor	Weak (IC50 ~0.1–1 mg/mL)	PSA kinetics RCT; null on serum Gal-3	Widely available	~$4/day at 14.4g
Fucoidan	Marine polysaccharide	CRD binding + Gal-3 secretion suppression	Unknown in humans	Animal only (2024 cardiac model)	Widely available	~$0.30–1/day
Selvigaltin (GB1211)	Small molecule	High-affinity CRD competitive inhibitor	Very high (KD = 25 nM)	Phase 1–2, not published	Investigational only	N/A
Belapectin	Polysaccharide (IV)	CRD inhibitor	Moderate	Phase 2/3 liver fibrosis	Investigational IV only	N/A
GB0139	Small molecule (inhaled)	CRD competitive inhibitor	High	Phase 2b IPF — failed	Discontinued	N/A
Quercetin	Flavonoid	Indirect: Gal-3/NLRP3 pathway	Indirect, uncertain	None direct	Widely available	~$0.20–0.50/day
Luteolin	Flavonoid	Indirect: Gal-3 signaling pathways	Indirect	None	Available	~$0.25–0.50/day
Curcumin	Polyphenol	Indirect: TGF-β, NF-κB overlap	Indirect	Extensive but not Gal-3 specific	Widely available	~$0.30–1/day

The Most Honest Framing

Of all commercially available options, PectaSol-C remains the only one with any published human clinical data specifically evaluating galectin-3 pathway effects — even if those results are mixed. Fucoidan is the next most pharmacologically plausible for direct Gal-3 inhibition, with a mechanistic rationale (suppressing secretion rather than only competitive binding) that could theoretically outperform MCP, but it has zero human data on Gal-3 specifically.

The massive potency gap between PectaSol-C (IC50 in mg/mL range) and investigational small molecules like selvigaltin (KD = 25 nM) is striking — it suggests that if selvigaltin or a successor makes it to market, it will make current supplement-tier galectin-3 inhibitors look pharmacologically primitive. That is likely 3–7 years away if development goes well.

For anyone building a galectin-3 inhibition protocol today, the pragmatic options are PectaSol-C (established benchmark), potentially combined with fucoidan (different and complementary mechanism, different molecular target site), with quercetin included for its Gal-3/NLRP3 pathway effects — which it likely provides anyway as part of a senolytic stack.

Sources:

qBx123Yk · June 13, 2026, 11:35pm

Dual GLP1/GCGR agonists have a tendency to increase egfr (without increasing hyperfiltration) , they might be a good candidate. SGLT-2 inhibitors don’t increase egfr, but slow down its decline, better than nothing.

qBx123Yk · June 14, 2026, 12:20am

Aren’t SGLT-2 inhibitors good enough for reducing LGALS3? They lower it’s expression indirectly, but the clinical outcomes vs direct inhibitors seem superior. AI summary of comparison follows.

Comparison of GLP1 agonists and SGLT2 inhibitors for decreasing expression

LGALS3An interesting intersection in modern cardiometabolic medicine involves the relationship between metabolic therapies and Galectin-3 (LGALS3/Gal-3). Gal-3 is a \beta-galactoside-binding lectin that serves as a core upstream driver of macro-phage polarization, chronic inflammation (metaflammation), and progressive tissue fibrosis (Liu, 2025; Otoda, 2025).
While GLP-1 receptor agonists (GLP-1 RAs), GLP-1/GCGR dual co-agonists, and SGLT2 inhibitors significantly mitigate Gal-3-mediated inflammatory and fibrotic pathologies, they do so through indirect downstream reduction rather than direct biochemical target inhibition.

1. GLP-1 and GLP-1/GCGR Co-Agonists vs. LGALS3

There is no clinical evidence demonstrating that GLP-1 RAs (such as semaglutide) or GLP-1/GCGR (Glucagon Receptor) co-agonists (such as oxyntomodulin derivatives or cotadutide) act as direct molecular inhibitors of LGALS3. They do not bind to or chemically block the carbohydrate recognition domain (CRD) of Gal-3.
However, strong indirect clinical and translational evidence shows they suppress the expression and downstream pathways of LGALS3:

The Mechanism: GLP-1 signaling significantly reduces systemic and localized low-grade chronic inflammation (Story, 2026; Ștefan, 2024). By downregulating the NF-\kappaB pathway and inhibiting macrophage activation, these agents shut off the cellular triggers that induce macrophages and myofibroblasts to secrete Gal-3 (Liu, 2025; Story, 2026).
Clinical Surrogates (MASH & Fibrosis): In clinical trials for Metabolic Dysfunction-Associated Steatohepatitis (MASH), semaglutide 2.4 mg achieved MASH resolution without worsening fibrosis in 62.9% of patients (Prikhodko, 2024; Ștefan, 2024). This structural preservation and reversal of tissue remodeling directly mirrors a massive downregulation of the Gal-3/TGF-\beta fibrotic axis, even though it is achieved via systemic metabolic improvements, weight loss, and reduced lipotoxicity (Prikhodko, 2024; Ștefan, 2024).

2. SGLT2 Inhibitors vs. LGALS3

Much like incretin mimetics, SGLT2 inhibitors (SGLT2is) like dapagliflozin and empagliflozin do not directly bind to or block the LGALS3 protein. However, their effect on Gal-3 expression and its relative prognostic power has been documented directly in clinical trial data.

Clinical Biomarker Trials

A crucial clinical analysis of this relationship comes from a nested biomarker substudy of the DECLARE-TIMI 58 trial involving 14,530 patients (Haller, 2025):

No Direct Lowering: The study observed that treatment with the SGLT2i dapagliflozin did not result in a consistent, significant lowering of circulating plasma Gal-3 levels compared to placebo (Haller, 2025; Otoda, 2025).
Targeting the Gal-3 Milieu: Patients with the highest baseline levels of Gal-3 (the highest quartile) had an elevated risk of progressive kidney dysfunction and heart failure events (Haller, 2025). Interestingly, these exact high-risk patients derived the greatest absolute risk reduction from dapagliflozin therapy (Haller, 2025; Otoda, 2025).

The Takeaway: Rather than eliminating Gal-3, SGLT2is heavily suppress the intracellular metabolic stress, lysosomal membrane permeabilization, and hemodynamic overload that make elevated Gal-3 so tissue-destructive (Huang, 2025; Otoda, 2025).

3. Comparison to Dedicated LGALS3 Inhibitors

Dedicated Galectin-3 inhibitors are specifically engineered to bind competitively to the carbohydrate recognition domain (CRD) of Gal-3, completely blocking its ability to cross-link glycoproteins and activate downstream fibrosis (Comeglio et al., 2024; Narvel, 2024).
The primary clinical candidates in this class include Belapectin (GR-MD-02) (a complex carbohydrate polymer) and Selvigaltin (GB1211) (an orally active small molecule) (Comeglio et al., 2024; Narvel, 2024).

Mechanism and Clinical Outcome Comparison

Attribute	SGLT2 Inhibitors / GLP-1 RAs	Dedicated LGALS3 Inhibitors (e.g., Belapectin, Selvigaltin)
Primary Target	SGLT2 cotransporters in kidneys; GLP-1 receptors in pancreas/brain.	The Carbohydrate Recognition Domain (CRD) of the LGALS3 protein.
Inhibition Method	Indirect: Decreases upstream inflammation, tissue stress, and macrophage recruitment.	Direct: Competitive biochemical antagonism of ligand binding.
MASH / Liver Fibrosis	Highly Effective: Heavy systemic metabolic clearance leads to profound steatohepatitis resolution (Prikhodko, 2024).	Mixed: Strong localized reduction in tissue biomarkers, but phase 2b trials (e.g., Belapectin) missed primary fibrosis endpoints except in selected subgroups without varices.
Cardiovascular Outcomes	Superior & Clear: Proven 20–30% reductions in MACE, cardiovascular death, and heart failure hospitalizations (Huang, 2025; Comșa, 2024).	Unproven: Currently confined to preclinical cardiovascular models or narrow oncology/cirrhosis trials; no macro-MACE reduction data exists.

Are Metabolic Agents Clinically Superior?

Yes, in terms of global clinical outcomes, metabolic inhibitors are vastly superior.
Dedicated Gal-3 inhibitors target a single downstream executioner molecule of fibrosis. While highly effective at reducing localized structural fibrogenesis in specific animal models (Comeglio et al., 2024; Liu, 2025), they do not fix the root metabolic abnormalities—such as insulin resistance, lipotoxicity, hyperfiltration, or systemic glucotoxicity—driving the disease state (Thiriet, 2018; Huang, 2025).
Conversely, by treating the underlying systemic metabolic failure, SGLT2is and GLP-1 RAs neutralize the entire upstream “fire.” The subsequent dampening of the Gal-3 fibro-inflammatory axis is a fortunate downstream result of comprehensive systemic protection (Otoda, 2025).

References & Study Links

DECLARE-TIMI 58 Substudy (Dapagliflozin & Gal-3): Haller et al. (2025) - Galectin‐3 and kidney function in type 2 diabetes treated with dapagliflozin
- Cited by: 3
Selvigaltin (GB1211) MASH Evidence: Comeglio et al. (2024) - The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis
- Cited by: 12
Gal-3 in Cardiovascular Residual Risk: Otoda et al. (2025) - Galectin-3 and the Glyco-Inflammatory Axis in Coronary Artery Disease
- Cited by: 1
Post-Myocardial Infarction Review: Liu et al. (2025) - Galectin-3 in acute myocardial infarction: from molecular mechanisms to clinical translation
- Cited by: 3
Incretin Therapies in MASH Pipeline: Prikhodko et al. (2024) / Ștefan et al. (2024) - Current Drug Development Pipeline for MASLD and MASH
Anti-inflammatory Pleiotropy: Comșa et al. (2024) - Anti-inflammatory Pathways of Novel Anti-diabetic Therapies
- Cited by: 3
SGLT2i Protective Mechanisms: Huang et al. (2025) - Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Heart Failure

While GLP-1 receptor agonists (GLP-1 RAs), GLP-1/GCGR dual co-agonists, and SGLT2 inhibitors significantly mitigate Gal-3-mediated inflammatory and fibrotic pathologies, they do so through indirect downstream reduction rather than direct biochemical target inhibition.

1. GLP-1 and GLP-1/GCGR Co-Agonists vs. LGALS3

There is no clinical evidence demonstrating that GLP-1 RAs (such as semaglutide) or GLP-1/GCGR (Glucagon Receptor) co-agonists (such as oxyntomodulin derivatives or cotadutide) act as direct molecular inhibitors of LGALS3. They do not bind to or chemically block the carbohydrate recognition domain (CRD) of Gal-3.
However, strong indirect clinical and translational evidence shows they suppress the expression and downstream pathways of LGALS3:

The Mechanism: GLP-1 signaling significantly reduces systemic and localized low-grade chronic inflammation (Story, 2026; Ștefan, 2024). By downregulating the NF-\kappaB pathway and inhibiting macrophage activation, these agents shut off the cellular triggers that induce macrophages and myofibroblasts to secrete Gal-3 (Liu, 2025; Story, 2026).
Clinical Surrogates (MASH & Fibrosis): In clinical trials for Metabolic Dysfunction-Associated Steatohepatitis (MASH), semaglutide 2.4 mg achieved MASH resolution without worsening fibrosis in 62.9% of patients (Prikhodko, 2024; Ștefan, 2024). This structural preservation and reversal of tissue remodeling directly mirrors a massive downregulation of the Gal-3/TGF-\beta fibrotic axis, even though it is achieved via systemic metabolic improvements, weight loss, and reduced lipotoxicity (Prikhodko, 2024; Ștefan, 2024).

2. SGLT2 Inhibitors vs. LGALS3

Much like incretin mimetics, SGLT2 inhibitors (SGLT2is) like dapagliflozin and empagliflozin do not directly bind to or block the LGALS3 protein. However, their effect on Gal-3 expression and its relative prognostic power has been documented directly in clinical trial data.

Clinical Biomarker Trials

A crucial clinical analysis of this relationship comes from a nested biomarker substudy of the DECLARE-TIMI 58 trial involving 14,530 patients (Haller, 2025):

No Direct Lowering: The study observed that treatment with the SGLT2i dapagliflozin did not result in a consistent, significant lowering of circulating plasma Gal-3 levels compared to placebo (Haller, 2025; Otoda, 2025).
Targeting the Gal-3 Milieu: Patients with the highest baseline levels of Gal-3 (the highest quartile) had an elevated risk of progressive kidney dysfunction and heart failure events (Haller, 2025). Interestingly, these exact high-risk patients derived the greatest absolute risk reduction from dapagliflozin therapy (Haller, 2025; Otoda, 2025).

The Takeaway: Rather than eliminating Gal-3, SGLT2is heavily suppress the intracellular metabolic stress, lysosomal membrane permeabilization, and hemodynamic overload that make elevated Gal-3 so tissue-destructive (Huang, 2025; Otoda, 2025).

3. Comparison to Dedicated LGALS3 Inhibitors

Dedicated Galectin-3 inhibitors are specifically engineered to bind competitively to the carbohydrate recognition domain (CRD) of Gal-3, completely blocking its ability to cross-link glycoproteins and activate downstream fibrosis (Comeglio et al., 2024; Narvel, 2024).
The primary clinical candidates in this class include Belapectin (GR-MD-02) (a complex carbohydrate polymer) and Selvigaltin (GB1211) (an orally active small molecule) (Comeglio et al., 2024; Narvel, 2024).

Mechanism and Clinical Outcome Comparison

Attribute	SGLT2 Inhibitors / GLP-1 RAs	Dedicated LGALS3 Inhibitors (e.g., Belapectin, Selvigaltin)
Primary Target	SGLT2 cotransporters in kidneys; GLP-1 receptors in pancreas/brain.	The Carbohydrate Recognition Domain (CRD) of the LGALS3 protein.
Inhibition Method	Indirect: Decreases upstream inflammation, tissue stress, and macrophage recruitment.	Direct: Competitive biochemical antagonism of ligand binding.
MASH / Liver Fibrosis	Highly Effective: Heavy systemic metabolic clearance leads to profound steatohepatitis resolution (Prikhodko, 2024).	Mixed: Strong localized reduction in tissue biomarkers, but phase 2b trials (e.g., Belapectin) missed primary fibrosis endpoints except in selected subgroups without varices.
Cardiovascular Outcomes	Superior & Clear: Proven 20–30% reductions in MACE, cardiovascular death, and heart failure hospitalizations (Huang, 2025; Comșa, 2024).	Unproven: Currently confined to preclinical cardiovascular models or narrow oncology/cirrhosis trials; no macro-MACE reduction data exists.

Are Metabolic Agents Clinically Superior?

Yes, in terms of global clinical outcomes, metabolic inhibitors are vastly superior.
Dedicated Gal-3 inhibitors target a single downstream executioner molecule of fibrosis. While highly effective at reducing localized structural fibrogenesis in specific animal models (Comeglio et al., 2024; Liu, 2025), they do not fix the root metabolic abnormalities—such as insulin resistance, lipotoxicity, hyperfiltration, or systemic glucotoxicity—driving the disease state (Thiriet, 2018; Huang, 2025).
Conversely, by treating the underlying systemic metabolic failure, SGLT2is and GLP-1 RAs neutralize the entire upstream “fire.” The subsequent dampening of the Gal-3 fibro-inflammatory axis is a fortunate downstream result of comprehensive systemic protection (Otoda, 2025).

References & Study Links

DECLARE-TIMI 58 Substudy (Dapagliflozin & Gal-3): Haller et al. (2025) - Galectin‐3 and kidney function in type 2 diabetes treated with dapagliflozin
- Cited by: 3
Selvigaltin (GB1211) MASH Evidence: Comeglio et al. (2024) - The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis
- Cited by: 12
Gal-3 in Cardiovascular Residual Risk: Otoda et al. (2025) - Galectin-3 and the Glyco-Inflammatory Axis in Coronary Artery Disease
- Cited by: 1
Post-Myocardial Infarction Review: Liu et al. (2025) - Galectin-3 in acute myocardial infarction: from molecular mechanisms to clinical translation
- Cited by: 3
Incretin Therapies in MASH Pipeline: Prikhodko et al. (2024) / Ștefan et al. (2024) - Current Drug Development Pipeline for MASLD and MASH
Anti-inflammatory Pleiotropy: Comșa et al. (2024) - Anti-inflammatory Pathways of Novel Anti-diabetic Therapies
- Cited by: 3
SGLT2i Protective Mechanisms: Huang et al. (2025) - Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Heart Failure

relaxedmeatball · June 15, 2026, 1:41am

Sorry I didn’t read any of the AI written stuff above. But I did read the study.

These proteins are being posited by this study as biomarkers.

They do show that interventions such as Rapamycin move those biomarkers? But it’s not exactly clear by how much. There are no concentration ranges given. The TACO tool is for uploading RNA-seq data - not really too applicable for any of us.

I don’t think there’s any evidence that lowering these protein itself (i.e. inhibiting LGALS3) slows aging/disease? Like the modified citrus pectin is apparently a way to inhibit LGALS3, but we don’t know that that would be able to influence progression of aging/disease. And certainly CDK2A1 (p21) is something you don’t want to go messing around with, since it’s a cell cycle regulator.

So despite the headline, there is almost nothing actionable here for a longevity enthusiast, but it’s potentially quite useful for a researcher to benchmark interventions using their calculator tool.

RapAdmin · June 16, 2026, 3:57am

I see it as more evidence that rapamycin, acarbose and SLGT2 inhibitors are likely to provide healthspan and lifespan benefits. The citrus pectin data seems to need more experimental evidence, from my perspective.

Question 1: Does the paper show rapamycin moves these biomarkers, and with what quantification?

Yes and no — and the distinction matters.

The paper’s intervention analysis operates at the transcriptomic (mRNA) level, not at the plasma protein level. The paper analyzed livers from mice exposed to 20 pharmacological interventions from the NIA Interventions Testing Program — including rapamycin, canagliflozin, 17α-oestradiol, captopril, and rapamycin+acarbose — and showed that lifespan-extending interventions reduce transcriptomic age: the gene expression signature of aging moves in a younger direction. Rapamycin is among the interventions that most robustly shift the clock. LGALS3, CDKN1A, and GPNMB are part of this transcriptomic signature, so when the paper says rapamycin “reduces transcriptomic age,” that implicitly includes their mRNA expression moving.

But there are no plasma protein concentration ranges given, for a structural reason: the two parts of the paper answer different questions and never intersect:

The intervention arm (rapamycin, etc.) measures gene expression in mouse tissues — it produces a transcriptomic age score, not ng/mL protein levels
The biomarker validation arm (UK Biobank, n>50,000) measures plasma proteins and links them to mortality via hazard ratios — but this is entirely observational; there is no interventional arm

So the paper never actually shows: “rapamycin treatment reduces plasma LGALS3 from X ng/mL to Y ng/mL.” It shows that rapamycin reduces the transcriptomic signature of which LGALS3 is a component, and separately that the plasma protein predicts mortality in observational data. Those two findings are consistent and complementary, but they are not the same claim, and the paper doesn’t bridge them with a number.

The quantitative outputs you can extract are: hazard ratios of ~1.1–1.6 per SD of protein level for all-cause mortality — but those are relative statistical associations in the UK Biobank population, not before/after values for any treatment.

Question 2: Is there evidence that inhibiting LGALS3 specifically slows aging or disease progression?

Your skepticism here is well-founded, and the honest answer is: not in any way the Tyshkovskiy paper demonstrates, and only partially from the broader literature.

What the paper actually establishes:
LGALS3 is a marker — a gene whose expression correlates with transcriptomic aging across species, and whose protein level predicts mortality in humans. The paper does not test whether targeting LGALS3 specifically slows aging. Rapamycin reduces the broader aging transcriptomic signature that includes LGALS3, but that doesn’t mean LGALS3 suppression is the mechanism by which rapamycin extends life. Rapamycin inhibits mTORC1, which has dozens of downstream effects on autophagy, protein synthesis, senescence, and metabolism. LGALS3 mRNA coming down could be an epiphenomenon — a consequence of cells becoming less inflamed and less senescent — rather than the causal pathway.

From the broader galectin-3 literature:
As we established earlier in this discussion, the causal evidence for galectin-3 in specific pathologies is reasonably strong — Lgals3-/- mice are protected from cardiac fibrosis, bone loss, and atherosclerosis, and recombinant galectin-3 injected into healthy rats produces cardiac fibrosis. So galectin-3 is genuinely causal for those organ-specific outcomes.

But — and this is the critical gap — no published study has shown that Lgals3-/- mice live longer. Protection from specific fibrotic pathologies is not the same as slowing the aging process itself. Lifespan extension in mice is a demanding bar: you need to see actual survival curves shift. That experiment has not been done and published.

On PectaSol-C specifically:
The inferential chain required to justify PectaSol-C as an aging intervention has at least four unproven links:

LGALS3 rises with aging and predicts mortality (documented — Tyshkovskiy 2026)
Galectin-3 is causally involved in fibrotic and other pathologies (documented — Lgals3-/- mice, gain-of-function data)
PectaSol-C meaningfully inhibits galectin-3 in humans (uncertain — the JACC RCT showed no reduction in circulating galectin-3 at 14.4 g/day)
Inhibiting galectin-3 slows aging or reduces age-related mortality in humans (undocumented)

The paper doesn’t establish link 4, the animal literature only partially establishes link 2 for specific pathologies, and the clinical data casts doubt on link 3. The leap from “this protein is a mortality biomarker” to “inhibiting this protein slows aging” is the standard biomarker-to-therapy gap — and it is a real gap here, not a small one.

The most defensible framing for PectaSol-C as a longevity intervention:
The rational case is not “this reverses aging” but rather “galectin-3 drives specific downstream pathologies — particularly cardiac fibrosis and possibly cancer progression — that contribute to age-related mortality, and blocking those specific pathways may reduce disease burden even if it doesn’t modify the primary aging process.” That is a more modest but more honest claim, and it is consistent with the existing evidence. The centenarian data (disease-free centenarians have very low galectin-3) supports this reading — they don’t have low galectin-3 because they’re young; they have low galectin-3 because they avoided the fibrotic and inflammatory cascade that kills most people before 100.

The paper itself concludes — accurately — that “further research is needed to determine how these molecular pathways can be safely targeted in humans.” That single sentence is a fair summary of where the evidence actually is.

Sources:

RapAdmin · June 16, 2026, 6:07am

A post was merged into an existing topic: Plasma proteomic signatures of cellular aging predict human disease

DrT · June 16, 2026, 12:25pm

I believe that gamma tocotrienol reduces the expression of Gal-3.

BarryAllen · June 16, 2026, 4:45pm

Greetings
I discontinued vitamin E supplements 15 or more years ago to get rid of the alpha tocopherol negative, and replaced with tocotrienols
Thanks for giving me another reason to use tocotrienols.
Here are some references:
γ-Tocotrienol inhibition of galectin-3 expression, distribution and oligomerization in highly metastatic breast cancer cells | Scientific Reports

and unfortunately paywalled:
Gamma Tocotrienol - an overview | ScienceDirect Topics

DrT · June 16, 2026, 9:27pm

Unfortunately it is only the gamma-tocotrienol that inhibits Gal-3 and it is the least abundant isomer. Annatto is the logical choice of supplement as it contains no tocopherols, but doses are low and expensive. I think there is a 30mg dose (10% of 300mg) by “Designer Health”?

relaxedmeatball · June 18, 2026, 3:00am

Yes, but one has to be careful of circular logic here. If you start by looking at successful ITP interventions to build your clock, then of course successful ITP interventions are going to move the clock.

To be honest, I find this very interesting, and it’s really awesome that they looked at ITP evidence, UK biobank etc. But, don’t forget that we already have a ton of very good and much more accessible biomarkers like NT-proBNP or GDF15 etc, not to mention hsCRP, RDW% etc which are very routine and can tell you a lot about your general health and ageing status.

So basically, I personally don’t see any value in trying to modify ones LGALS3 expression level. And it’s very likely IMO, if this is a marker of fibrosis, that the things we know are good - lower inflammation, exercise etc - are going to lower it for you.

Goran · June 18, 2026, 4:41pm

There’s always a bit of synchronicity on this site. Last month, I was researching Modified Citrus Pectin (MCP) and bought a couple of cans to get started. Then, last week, I had a deep discussion with Gemini AI about what could be the ultimate morning drink for a 56-year-old male like me. After a lot of thought and consideration, the results were:

5 grams of Modified Citrus Pectin
300 mg of NMN
1 teaspoon of L-Lysine
5 grams of Beetroot powder
5 grams of Creatine
10 grams of Collagen

Mix these ingredients with 1/2 liter of room temperature green tea.

I have to say, it really works! I feel great. With increased energy and concentration, I didn’t have before starting this. I highly recommend everyone to try it. It’s not very expensive.

zebit0 · October 12, 2026, 1:23pm

Another and more recently article on “protein signature” in blood that could predict healthy aging:

"In a new study, published Friday (Oct. 9) in the journal Immunity, scientists found that individuals with more memory cells that make granzyme K than cells that make granzyme B tend to have healthier aging.

In the future, the balance of cells making granzyme K and granzyme B in a person’s blood could be used as a test to determine “whether you’re on the right trajectory of aging or not,” study co-author Maxim Artyomov, an immunologist at Washington University in St. Louis, told Live Science."

AI generated summary:

Your T-cell mix may track how you’re aging, but the test behind the claim hasn’t been run

Bottom line

As people age, a group of memory immune cells (CD8 effector memory T cells) tends to tilt one of two ways. Some people end up dominated by cells that make granzyme K, and they tend to have fewer chronic conditions. Others end up dominated by cells that make granzyme B, and that tilt goes with CMV infection, autoimmune disease and comorbidity. In 48,620 UK Biobank participants, a blood-protein estimate of the granzyme B side predicted modestly higher death rates and more diabetes, kidney failure, liver disease and sepsis over about 17 years. There’s nothing to act on yet: no clinical test exists and no intervention has been tried. The long-term link rests on an indirect estimate of half the ratio, adjusted only for age and sex.

The study in plain English

Part 1: an immune atlas (one snapshot in time). The authors pooled single-cell sequencing of blood from 2,609 “ostensibly healthy” adults aged 18–97, across 8 cohorts and about 12 million cells. Participants were mostly of European and Asian ancestry. The most reproducible aging signal was thymic decline: the loss of new and naive T cells. Among older people, the cells split toward the granzyme K or granzyme B side.

The ratio itself barely moves with age. What drives it down is:

CMV infection, the strongest driver
lupus
comorbidity, though that comparison rests on only 23 older people with chronic conditions in the new King’s College London cohort

Part 2: UK Biobank (followed over time, but indirect). UK Biobank has no single-cell data. So the authors trained a model on 329 people to estimate the share of granzyme B cells from blood proteins. In testing on people it hadn’t been trained on, that estimate explained only about a quarter of the real variation. They then applied it to 48,620 people.

Results. Among 60–70-year-olds, about 27 in 100 people in the top quarter of the score died over roughly 16 years, versus about 19 in 100 in the bottom quarter. That’s about 8 extra deaths per 100, read off the survival curves. The age- and sex-adjusted HR was 1.43. For scale, being male in the same model carried an HR of 1.66. The score also predicted:

type 2 diabetes (HR 1.74)
gout (1.80)
kidney failure (1.60)
liver disease (1.74)
sepsis (1.50)

There was no signal for dementia, Alzheimer’s or Parkinson’s.

Why it matters

Should you care? The biology is genuinely interesting. Immune aging looks like two diverging paths rather than one slope, and the paper finds a measurable axis with a likely driver (CMV). It’s a sharper version of the old Swedish “immune risk profile” (an inverted CD4:CD8 ratio plus CMV). As a predictor, though, nobody has shown it adds anything. The authors didn’t test it against hs-CRP, kidney function, HbA1c, or the existing UK Biobank proteomic aging clock, which already predicts death and 18 diseases (Argentieri 2024).

Actionability: none.

No test. Standard clinical flow cytometry can’t tell these cells apart. Measuring them takes single-cell sequencing or specialized staining.
No intervention. Nothing has been shown to shift the ratio, and nobody has shown that shifting it would change outcomes.
No handle on the main driver. There’s no CMV vaccine, and treating latent CMV in healthy people isn’t indicated.
Nothing to add to a biomarker panel. The protein score tracks CRP and IL-6. You can already measure hs-CRP.

Don’t read “more granzyme K is good” literally. In tissue, granzyme K–producing CD8 cells drive inflammation: granzyme K activates the entire complement cascade and is implicated in rheumatoid arthritis (Donado, Nature 2025). In mice, these same authors earlier tagged granzyme K cells as the cells behind age-related inflammation. The “good” signal applies only to the ratio in circulating blood. Anyone selling a granzyme K product off this paper is selling nonsense.

Caveats and blind spots

The headline claim isn’t what was tested over time. UK Biobank never measured the ratio. It measured a protein proxy for the granzyme B side only. The top proxy proteins (GNLY, KLRD1, GZMH) are also abundant in NK cells, so the score may be a general “cytotoxic and inflammatory load” reading rather than a T-cell measurement.
The adjustment is thin. The models adjust only for age and sex: not smoking, BMI, alcohol, deprivation, kidney function or existing disease. The outcomes that light up (diabetes, gout, liver and kidney disease) are classic metabolic outcomes. Much of the signal could simply mean that sicker, more inflamed people die sooner.
Reverse causation. The score was higher in people who already had long-standing illness. The mortality analysis didn’t exclude existing disease. Artyomov himself told Live Science the ratio “might be just a consequence, not a cause.”
CMV wasn’t adjusted for in the mortality model. The CMV–mortality link is itself contested. Some UK cohorts found one (Savva 2013); a pooled analysis of about 10,000 older adults found none (Chen, JID 2021).
Other gaps.
- Nobody was sampled twice, so we don’t know whether a person’s ratio is stable.
- There’s no medication data.
- African and Hispanic ancestry are underrepresented.
- UK Biobank skews healthy and mostly white British.
Conflict of interest. Five authors, including Artyomov, are named on a provisional patent application “involving matters related to this study.” That’s useful context for his “future test” quote. Funding came from the nonprofit Aging Biology Foundation and NIH, with no industry sponsor.

Strengths: It’s peer reviewed in Immunity and large. Findings counted only if they replicated in at least 5 of the 8 cohorts. Data and code are open, and the null results were reported.

Verdict: 3/5 (interesting but preliminary)

The atlas alone would earn a 4: it’s large, replicated across cohorts and transparent. The clinical claim alone is closer to a 2. It rests on a weak proxy for half the ratio, adjusted only for age and sex, never compared against existing markers, and promoted by authors with a pending patent. Overall it’s real biology pointing in a direction, with nothing to act on yet.

Sources:

zebit0 · October 12, 2026, 2:00pm

I ran this thread alongside the more recently Immunity paper (Terekhova et al., Oct 2026) on the granzyme K/B T-cell ratio and aging. Both come from the same UK Biobank proteomics setup and have a similar structure: a protein signal tied to mortality, followed by the question of whether anything can be done about it. Some notes, with the caveat that I read abstracts and summaries rather than full texts for much of the galectin-3 side.

Areas of agreement:

A mortality biomarker isn’t the same as a therapeutic target. Rapamycin lowering LGALS3 expression could be a downstream effect of less inflammation rather than the mechanism.
Routine markers (NT-proBNP, hs-CRP, GDF-15, cystatin C) may already capture much of this signal. The papers I’ve seen don’t test whether galectin-3 adds anything beyond them.
No published study I’m aware of shows that Lgals3-knockout mice live longer.

Things worth double-checking if we discuss PectaSol-C

The Phase II PSA study is Keizman et al., Nutrients 2021. It was single-arm (no placebo), 59 patients, and funded by EcoNugenics, with its founder as a co-author. The results are encouraging for PSA doubling time, but that endpoint can’t separate the supplement’s effect from natural variation.
Selvigaltin (GB1211) is another oral galectin-3 inhibitor with early human data in cirrhosis, so MCP may not be the only option.
Evidence that 14.4 g/day measurably lowers circulating galectin-3 in humans looks thin. The hypertension RCT (Lau 2021) is the main controlled data point I could find.
None of this says MCP doesn’t work, only that the evidence for it as a longevity intervention is still early.

For comparison, the granzyme paper has the same gap. The UK Biobank result uses a protein-based estimate of one half of the ratio, adjusted for age and sex only, and there’s no intervention data.

Has anyone seen full-text data on whether MCP actually lowers circulating galectin-3 at trial doses? That seems like the key missing link.

RapAdmin · October 12, 2026, 4:30pm

Yes - we covered it here: Men Lose Thymic Output Faster: Sex Differences and Other Usable Findings From a Global Immune Atlas

What LLM/AI are you using, and what model (e.g. Gemini 3.1 Pro, High)? Are you using a “Free” LLM, or are you paying for it?, and how are you running the analysis (do you upload the PDF to the LLM, or just point it to the URL? I always upload the full PDF of the paper, for analysis. it’s interesting to compare the different outputs.

John_Hemming · October 12, 2026, 5:20pm

The granzyme B creation looks to be to get rid of proteins that are a nuisance.